Cargando…

基于中国胸腺瘤协作组回顾性数据库对比Masaoka-Koga分期和国际肺癌协会/国际胸腺肿瘤协作组提出的TNM分期系统

BACKGROUND AND OBJECTIVE: To compare the predictive effect of the Masaoka-Koga staging system and the International Association for the Study of Lung Cancer (IASLC)/the International Thymic Malignancies Interest Group(ITMIG) proposal for the new TNM staging on prognosis of thymic malignancies using...

Descripción completa

Detalles Bibliográficos
Autor principal: WEI, Yucheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6133977/
https://www.ncbi.nlm.nih.gov/pubmed/27339719
http://dx.doi.org/10.3779/j.issn.1009-3419.2016.07.04
_version_ 1783354584580751360
author WEI, Yucheng
author_facet WEI, Yucheng
collection PubMed
description BACKGROUND AND OBJECTIVE: To compare the predictive effect of the Masaoka-Koga staging system and the International Association for the Study of Lung Cancer (IASLC)/the International Thymic Malignancies Interest Group(ITMIG) proposal for the new TNM staging on prognosis of thymic malignancies using the Chinese Alliance for Research in Thymomas (ChART) retrospective database. METHODS: From 1992 to 2012, 2, 370 patients in ChART database were retrospectively reviewed. Of these, 1, 198 patients with complete information on TNM stage, Masaoka-Koga stage, and survival were used for analysis. Cumulative incidence of recurrence (CIR) was assessed in R0 patients. Overall survival (OS) was evaluated both in an R0 resected cohort, as well as in all patients (any R status). CIR and OS were first analyzed according to the Masaoka-Koga staging system. Then, they were compared using the new TNM staging proposal. RESULTS: Based on Masaoka- Koga staging system, significant difference was detected in CIR among all stages. However, No survival difference was revealed between stage Ⅰ and Ⅱ, or between stage Ⅱ and Ⅲ. Stage Ⅳ carried the highest risk of recurrence and worst survival. According to the new TNM staging proposal, CIR in T1a was significantly lower comparing to all other T categories (P < 0.05) and there is a significant difference in OS between T1a and T1b (P=0.004). T4 had the worst OS comparing to all other T categories. CIR and OS were significantly worse in N(+) than in N0 patients. Significant difference in CIR and OS was detected between M0 and M1b, but not between M0 and M1a. OS was almost always statistically different when comparison was made between stages Ⅰ-Ⅲa and stages Ⅲb-Ⅳb. However, no statistical difference could be detected among stages Ⅲb to Ⅳb. CONCLUSION: Compared with Masaoka-Koga staging, the IASLC/ITMIG TNM staging proposal not only describes the extent of tumor invasion but also provides information on lymphatic involvement and tumor dissemination. Further study using prospectively recorded information on the proposed TNM categories would be helpful to better grouping thymic tumors for predicting prognosis and guiding clinical management.
format Online
Article
Text
id pubmed-6133977
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-61339772018-10-02 基于中国胸腺瘤协作组回顾性数据库对比Masaoka-Koga分期和国际肺癌协会/国际胸腺肿瘤协作组提出的TNM分期系统 WEI, Yucheng Zhongguo Fei Ai Za Zhi 2016胸外医师年会特约专题:胸腺肿瘤 BACKGROUND AND OBJECTIVE: To compare the predictive effect of the Masaoka-Koga staging system and the International Association for the Study of Lung Cancer (IASLC)/the International Thymic Malignancies Interest Group(ITMIG) proposal for the new TNM staging on prognosis of thymic malignancies using the Chinese Alliance for Research in Thymomas (ChART) retrospective database. METHODS: From 1992 to 2012, 2, 370 patients in ChART database were retrospectively reviewed. Of these, 1, 198 patients with complete information on TNM stage, Masaoka-Koga stage, and survival were used for analysis. Cumulative incidence of recurrence (CIR) was assessed in R0 patients. Overall survival (OS) was evaluated both in an R0 resected cohort, as well as in all patients (any R status). CIR and OS were first analyzed according to the Masaoka-Koga staging system. Then, they were compared using the new TNM staging proposal. RESULTS: Based on Masaoka- Koga staging system, significant difference was detected in CIR among all stages. However, No survival difference was revealed between stage Ⅰ and Ⅱ, or between stage Ⅱ and Ⅲ. Stage Ⅳ carried the highest risk of recurrence and worst survival. According to the new TNM staging proposal, CIR in T1a was significantly lower comparing to all other T categories (P < 0.05) and there is a significant difference in OS between T1a and T1b (P=0.004). T4 had the worst OS comparing to all other T categories. CIR and OS were significantly worse in N(+) than in N0 patients. Significant difference in CIR and OS was detected between M0 and M1b, but not between M0 and M1a. OS was almost always statistically different when comparison was made between stages Ⅰ-Ⅲa and stages Ⅲb-Ⅳb. However, no statistical difference could be detected among stages Ⅲb to Ⅳb. CONCLUSION: Compared with Masaoka-Koga staging, the IASLC/ITMIG TNM staging proposal not only describes the extent of tumor invasion but also provides information on lymphatic involvement and tumor dissemination. Further study using prospectively recorded information on the proposed TNM categories would be helpful to better grouping thymic tumors for predicting prognosis and guiding clinical management. 中国肺癌杂志编辑部 2016-07-20 /pmc/articles/PMC6133977/ /pubmed/27339719 http://dx.doi.org/10.3779/j.issn.1009-3419.2016.07.04 Text en 版权所有©《中国肺癌杂志》编辑部2016 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/
spellingShingle 2016胸外医师年会特约专题:胸腺肿瘤
WEI, Yucheng
基于中国胸腺瘤协作组回顾性数据库对比Masaoka-Koga分期和国际肺癌协会/国际胸腺肿瘤协作组提出的TNM分期系统
title 基于中国胸腺瘤协作组回顾性数据库对比Masaoka-Koga分期和国际肺癌协会/国际胸腺肿瘤协作组提出的TNM分期系统
title_full 基于中国胸腺瘤协作组回顾性数据库对比Masaoka-Koga分期和国际肺癌协会/国际胸腺肿瘤协作组提出的TNM分期系统
title_fullStr 基于中国胸腺瘤协作组回顾性数据库对比Masaoka-Koga分期和国际肺癌协会/国际胸腺肿瘤协作组提出的TNM分期系统
title_full_unstemmed 基于中国胸腺瘤协作组回顾性数据库对比Masaoka-Koga分期和国际肺癌协会/国际胸腺肿瘤协作组提出的TNM分期系统
title_short 基于中国胸腺瘤协作组回顾性数据库对比Masaoka-Koga分期和国际肺癌协会/国际胸腺肿瘤协作组提出的TNM分期系统
title_sort 基于中国胸腺瘤协作组回顾性数据库对比masaoka-koga分期和国际肺癌协会/国际胸腺肿瘤协作组提出的tnm分期系统
topic 2016胸外医师年会特约专题:胸腺肿瘤
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6133977/
https://www.ncbi.nlm.nih.gov/pubmed/27339719
http://dx.doi.org/10.3779/j.issn.1009-3419.2016.07.04
work_keys_str_mv AT jīyúzhōngguóxiōngxiànliúxiézuòzǔhuígùxìngshùjùkùduìbǐmasaokakogafēnqīhéguójìfèiáixiéhuìguójìxiōngxiànzhǒngliúxiézuòzǔtíchūdetnmfēnqīxìtǒng
AT jīyúzhōngguóxiōngxiànliúxiézuòzǔhuígùxìngshùjùkùduìbǐmasaokakogafēnqīhéguójìfèiáixiéhuìguójìxiōngxiànzhǒngliúxiézuòzǔtíchūdetnmfēnqīxìtǒng
AT jīyúzhōngguóxiōngxiànliúxiézuòzǔhuígùxìngshùjùkùduìbǐmasaokakogafēnqīhéguójìfèiáixiéhuìguójìxiōngxiànzhǒngliúxiézuòzǔtíchūdetnmfēnqīxìtǒng
AT jīyúzhōngguóxiōngxiànliúxiézuòzǔhuígùxìngshùjùkùduìbǐmasaokakogafēnqīhéguójìfèiáixiéhuìguójìxiōngxiànzhǒngliúxiézuòzǔtíchūdetnmfēnqīxìtǒng
AT jīyúzhōngguóxiōngxiànliúxiézuòzǔhuígùxìngshùjùkùduìbǐmasaokakogafēnqīhéguójìfèiáixiéhuìguójìxiōngxiànzhǒngliúxiézuòzǔtíchūdetnmfēnqīxìtǒng
AT weiyucheng jīyúzhōngguóxiōngxiànliúxiézuòzǔhuígùxìngshùjùkùduìbǐmasaokakogafēnqīhéguójìfèiáixiéhuìguójìxiōngxiànzhǒngliúxiézuòzǔtíchūdetnmfēnqīxìtǒng
AT jīyúzhōngguóxiōngxiànliúxiézuòzǔhuígùxìngshùjùkùduìbǐmasaokakogafēnqīhéguójìfèiáixiéhuìguójìxiōngxiànzhǒngliúxiézuòzǔtíchūdetnmfēnqīxìtǒng
AT jīyúzhōngguóxiōngxiànliúxiézuòzǔhuígùxìngshùjùkùduìbǐmasaokakogafēnqīhéguójìfèiáixiéhuìguójìxiōngxiànzhǒngliúxiézuòzǔtíchūdetnmfēnqīxìtǒng
AT jīyúzhōngguóxiōngxiànliúxiézuòzǔhuígùxìngshùjùkùduìbǐmasaokakogafēnqīhéguójìfèiáixiéhuìguójìxiōngxiànzhǒngliúxiézuòzǔtíchūdetnmfēnqīxìtǒng
AT jīyúzhōngguóxiōngxiànliúxiézuòzǔhuígùxìngshùjùkùduìbǐmasaokakogafēnqīhéguójìfèiáixiéhuìguójìxiōngxiànzhǒngliúxiézuòzǔtíchūdetnmfēnqīxìtǒng
AT jīyúzhōngguóxiōngxiànliúxiézuòzǔhuígùxìngshùjùkùduìbǐmasaokakogafēnqīhéguójìfèiáixiéhuìguójìxiōngxiànzhǒngliúxiézuòzǔtíchūdetnmfēnqīxìtǒng
AT jīyúzhōngguóxiōngxiànliúxiézuòzǔhuígùxìngshùjùkùduìbǐmasaokakogafēnqīhéguójìfèiáixiéhuìguójìxiōngxiànzhǒngliúxiézuòzǔtíchūdetnmfēnqīxìtǒng
AT jīyúzhōngguóxiōngxiànliúxiézuòzǔhuígùxìngshùjùkùduìbǐmasaokakogafēnqīhéguójìfèiáixiéhuìguójìxiōngxiànzhǒngliúxiézuòzǔtíchūdetnmfēnqīxìtǒng
AT jīyúzhōngguóxiōngxiànliúxiézuòzǔhuígùxìngshùjùkùduìbǐmasaokakogafēnqīhéguójìfèiáixiéhuìguójìxiōngxiànzhǒngliúxiézuòzǔtíchūdetnmfēnqīxìtǒng
AT jīyúzhōngguóxiōngxiànliúxiézuòzǔhuígùxìngshùjùkùduìbǐmasaokakogafēnqīhéguójìfèiáixiéhuìguójìxiōngxiànzhǒngliúxiézuòzǔtíchūdetnmfēnqīxìtǒng
AT jīyúzhōngguóxiōngxiànliúxiézuòzǔhuígùxìngshùjùkùduìbǐmasaokakogafēnqīhéguójìfèiáixiéhuìguójìxiōngxiànzhǒngliúxiézuòzǔtíchūdetnmfēnqīxìtǒng
AT jīyúzhōngguóxiōngxiànliúxiézuòzǔhuígùxìngshùjùkùduìbǐmasaokakogafēnqīhéguójìfèiáixiéhuìguójìxiōngxiànzhǒngliúxiézuòzǔtíchūdetnmfēnqīxìtǒng
AT jīyúzhōngguóxiōngxiànliúxiézuòzǔhuígùxìngshùjùkùduìbǐmasaokakogafēnqīhéguójìfèiáixiéhuìguójìxiōngxiànzhǒngliúxiézuòzǔtíchūdetnmfēnqīxìtǒng
AT jīyúzhōngguóxiōngxiànliúxiézuòzǔhuígùxìngshùjùkùduìbǐmasaokakogafēnqīhéguójìfèiáixiéhuìguójìxiōngxiànzhǒngliúxiézuòzǔtíchūdetnmfēnqīxìtǒng
AT jīyúzhōngguóxiōngxiànliúxiézuòzǔhuígùxìngshùjùkùduìbǐmasaokakogafēnqīhéguójìfèiáixiéhuìguójìxiōngxiànzhǒngliúxiézuòzǔtíchūdetnmfēnqīxìtǒng
AT jīyúzhōngguóxiōngxiànliúxiézuòzǔhuígùxìngshùjùkùduìbǐmasaokakogafēnqīhéguójìfèiáixiéhuìguójìxiōngxiànzhǒngliúxiézuòzǔtíchūdetnmfēnqīxìtǒng
AT jīyúzhōngguóxiōngxiànliúxiézuòzǔhuígùxìngshùjùkùduìbǐmasaokakogafēnqīhéguójìfèiáixiéhuìguójìxiōngxiànzhǒngliúxiézuòzǔtíchūdetnmfēnqīxìtǒng
AT jīyúzhōngguóxiōngxiànliúxiézuòzǔhuígùxìngshùjùkùduìbǐmasaokakogafēnqīhéguójìfèiáixiéhuìguójìxiōngxiànzhǒngliúxiézuòzǔtíchūdetnmfēnqīxìtǒng